Small Cap Feast
Small Cap Feast – 08 January 2020
Set Menu AIM:
Total number of AIM Companies (Incl Susp):
Total number of AIM Companies trading: *
* As at
Set Menu NEX Growth:
Total number of NEX Growth Market Companies (Incl Susp): *
Total number of NEX Growth Market Companies trading: *
* As at
Set Menu Standard List:
Total number of Standard List Companies (Incl Susp): *
Total number of Standard List Companies trading: *
* As at
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
Avesoro Resources and Brady have both left AIM after being acquired.
Avesoro Resources and Brady have both left AIM after being acquired.
Dish of the Day:
Off the Menu:
What’s Cooking in the IPO Kitchen?
Main Market (Premium)
The Global Sustainable Farmland Income Trust will invest in a diversified portfolio of operational farmland assets located in major agricultural markets including the United States, Europe, New Zealand, Australia and certain countries within Latin and South America. Raising up to $300m. Due 28 February
Rumours and Speculation
Investment firm Nippon Active Value Fund is seeking to raise up to £200m at an issue price of 100p per share via an IPO. The company aims to invest in a portfolio of quoted Japanese stocks with market capitalisations of up to $1bn. First day of dealings expected early February.
HML Holdings (HMLH.L) 34.5p £15.1m
The provider of property management, insurance and ancillary services to residential property blocks, has acquired Leasehold Management Limited (“LML”) for a consideration of £438,000 plus an additional payment for the surplus working capital .
- LML specialises in leasehold management and is based in Worthing
- LML will be integrated into HML over the coming months with employees remaining with the business, save for LML founder Peter Ballam who will be retiring.
. LML manages 1,222 units in 81 blocks.
Ebiquity (EBQ.L) 38p £30.4m
The independent marketing and media consultancy, today announces the acquisition of Digital Decisions, a digital media monitoring and optimisation service, for an initial consideration of EUR0.7 million. The acquisition is highly complementary to Ebiquity’s Media division and will enhance the services that it offers to its global client base.
Digital Decisions’ solutions have been adopted by a number of global brands including Heineken and PepsiCo. Joseph Hernandez, Senior Director Media and Connections Planning at PepsiCo said “Digital Decisions and Ebiquity are a perfect match, future-proofing ad spend efficiency drivers in a digital age”.
For the 18-month period to 31 December 2018 (its first financial period), Digital Decisions reported revenue of EUR419,000, profit before tax of EUR118,000 and as at 31 December 2018 had gross assets of EUR151,000.
Mpac Group (MPAC.L) 228.5p £46m
The “global leader in ‘Make, Pack, Monitor and Service’ high speed packaging and automation solutions, provides a pre-close trading update (unaudited) for the year ended 31 December 2019.
On 5 September 2019, the Group reported that its profits for FY19 were expected to be significantly above the Board’s and market expectations, with the momentum gained earlier in the year continuing throughout the second half of the year. The Board is delighted to announce that since that date, momentum in the business has continued to accelerate and we expect to report a full year trading performance ahead of these upgraded expectations. This is primarily as the result of a strong Q4 order intake and accelerated project execution.
Alongside this, continued progress has been made in realising the financial benefits of the strategic plans of delivering on the ‘One Mpac’ business model. The Group remains focused on the continued successful execution of its long-term strategy of developing our Services business, sustaining the Original Equipment order intake growth and converting operational efficiencies into improved financial performance and cash generation.”
Intelligent Ultrasound Group (MED.L) 11p £24.2m
Group revenue for the year to 31 December 2019, which is currently generated entirely by the Group’s Simulation Division, is expected to grow by around 10% from the £5.3m achieved in 2018 to between £5.7m and £5.9m. The Group is pleased that the Division continued to show year on year growth and the important agreement signed with FUJIFILM SonoSite Inc. in H2, will help increase future sales in the Division’s point-of-care ultrasound (POCUS) training market.
The Group’s pre-revenue Clinical AI Division had a very successful year, meeting all its commercial and development milestones. By signing its first long-term licence and co-development agreement in July 2019 with one of the world’s leading ultrasound equipment manufacturers for its AI-based real-time ultrasound imaging software, the Group made a significant advance in validating its commercial model.
The EBITDA loss for the year is expected to be between £3.3m and £3.4m (2018: loss, £2.7m). This includes c. £2.0m (2018: £1.3m) of primarily R&D costs attributable to investment in the Group’s Clinical AI Division.
Shield Therapeutics (STX.L) 179p £210m
Exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co. Ltd for the development and commercialisation of Feraccru®/Accrufer® in China
- US$11.4 million upfront licence payment to Shield
- Up to US$51.4 million in development and sales milestones
- Ongoing tiered double-digit royalties on net sales payable to Shield
- ASK Pharm to be responsible for, and cover costs of, all development and regulatory activity
Sirius Minerals (SXX.L) 5.5p £385m
Sirius is in advanced discussions with Anglo American Plc (“Anglo American”) regarding a possible all cash offer of 5.50 pence per Sirius share for the entire issued, and to be issued, share capital of Sirius .
The Proposal represents a premium of:
– 34.1% to the closing price of 4.10 pence per Sirius share on 7 January 2020, being the last business day prior to the date of this announcement;
Good Energy (GOOD.L) 213p £35.4m
“Good Energy Group PLC, the 100% renewable electricity supplier and innovative energy services provider, is pleased to announce the appointment of Rupert Sanderson as Chief Financial Officer (CFO) and Executive Director to the Board of the Company with effect from 8 January 2020.
Rupert joined Good Energy in February 2017 and was appointed Finance Director in January 2018 and is responsible for finance, trading, legal and investor relations. His previous roles include senior financial and commercial positions at Centrica, British Gas, Serco and Avis Europe. Rupert began his career as an accountant for PwC and is a Fellow of the Institute of Chartered Accountants in England and Wales.”
AdEPT Tech (ADT.L) 332p £78.7m
“In 2018 AdEPT announced a significant government contract win with the NHS. However, winning a contract is only half the battle – it is crucial to deliver on the promise made in this substantial contract process.
AdEPT is therefore delighted to announce that, under the guidance of the NHS Trusts in Kent, AdEPT has delivered improved network and bandwidth capacity to more than 100 hospital and specialist care sites across the region.
This project facilitates greater collaboration in handling the health and welfare needs of Kent residents.
Following the success of this initial network programme, AdEPT are completing the roll-out of improved bandwidth services to the 300 GP surgeries in the region. This will complete the upgrade of the entire NHS network in Kent.”
Rosslyn Data Tech (RDT.L) 4.7p £9.1m
The global big data technology company, announces that it has won two large contracts with a minimum combined contract value of £0.9 million over their minimum term. The contracts are for delivery of Knowledge Capture part of Rosslyn’s Information Management suite of products.
Alpha FX (AFX.L) 1245p £462m
The foreign exchange and payments specialist working for corporates and institutions internationally, today announces a trading update for the year ended 31 December 2019.
Following the last trading update on 17 October 2019, trading has continued to be strong, with revenues for the FY expected to exceed £35m and pre-tax profit margin also slightly ahead of expectations despite continued investments made throughout the year.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.